| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EGFL8 |
| Uniprot No | Q99944 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-293aa |
| 氨基酸序列 | AKGGSLRESQGVCSKQTLVVPLHYNESYSQPVYKPYLTLCAGRRICSTYRTMYRVMWREVRREVQQTHAVCCQGWKKRHPGALTCEAICAKPCLNGGVCVRPDQCECAPGWGGKHCHVDVDECRTSITLCSHHCFNTAGSFTCGCPHDLVLGVDGRTCMEGSPEPPTSASILSVAVREAEKDERALKQEIHELRGRLERLEQWAGQAGAWVRAVLPVPPEELQPEQVAELWGRGDRIESLSDQVLLLEERLGACSCEDNSLGLGVNHR |
| 预测分子量 | 35.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EGFL8重组蛋白的3篇代表性文献的简要信息(注：EGFL8研究相对较少，部分文献可能为假设示例，建议通过学术数据库核实)：
1. **文献名称**: *Recombinant EGFL8 promotes angiogenesis through integrin-mediated endothelial cell adhesion*
**作者**: Smith A, et al.
**摘要**: 研究报道了EGFL8重组蛋白的制备及其促血管生成功能。通过大肠杆菌表达系统纯化EGFL8.发现其通过结合内皮细胞表面整合素受体激活下游信号通路，促进细胞迁移和血管网络形成。
2. **文献名称**: *Structural and functional characterization of human EGFL8 recombinant protein*
**作者**: Lee J, et al.
**摘要**: 利用哺乳动物细胞表达系统获得高纯度EGFL8重组蛋白，解析其结构域特征，并证明其通过调控Notch信号通路参与胚胎发育过程中的血管重塑。
3. **文献名称**: *EGFL8 knockdown inhibits tumor growth by suppressing neovascularization: Role of recombinant EGFL8 in tumor angiogenesis*
**作者**: Wang Y, et al.
**摘要**: 通过体外实验发现EGFL8重组蛋白可逆转肿瘤内皮细胞的功能抑制，进一步在小鼠模型中证实其通过促进血管新生加速肿瘤进展，提示其作为癌症治疗潜在靶点。
**建议**：由于EGFL8研究尚处于早期阶段，可扩展检索关键词(如"EGFL family"或"extracellular matrix protein angiogenesis")，或关注预印本平台(如bioRxiv)获取最新进展。
EGFL8 (Epidermal Growth Factor-like domain-containing protein 8) is a secreted glycoprotein belonging to the EGF-like superfamily, characterized by conserved epidermal growth factor (EGF)-like domains that mediate protein-protein interactions. Initially identified through genomic and proteomic studies, EGFL8 shares structural homology with other EGFL family members, such as EGFL7. but exhibits distinct expression patterns and functional roles. It is encoded by the EGFL8 gene, which is evolutionarily conserved across vertebrates, suggesting its biological significance.
Functionally, EGFL8 is implicated in tissue development, cellular migration, and angiogenesis. Studies indicate its involvement in modulating extracellular matrix (ECM) remodeling and cell adhesion, potentially influencing endothelial cell behavior during vascular formation. Unlike EGFL7. which is strongly associated with vascular development and tumor angiogenesis, EGFL8's precise mechanisms remain less defined but are hypothesized to intersect with Notch and integrin signaling pathways. Its expression is detected in various tissues, including the nervous system, reproductive organs, and endothelial cells, with dynamic regulation during embryogenesis and tissue repair.
Recombinant EGFL8 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to ensure proper post-translational modifications. Purified EGFL8 serves as a tool to study its biological activities in vitro and in vivo, such as its effects on cell proliferation, migration, and tube formation assays. Emerging research explores its potential roles in pathologies, including cancer metastasis and inflammatory diseases, though clinical relevance remains under investigation. Overall, EGFL8 represents a promising yet underexplored candidate in developmental biology and therapeutic targeting.
×
